SODIUM PHOSPHATES
Clinical safety rating
cautionComprehensive clinical and safety monograph for SODIUM PHOSPHATES (SODIUM PHOSPHATES).
Sodium phosphates act as a source of phosphate and sodium ions. Phosphate is an essential component of bone mineral, cell membranes, and energy metabolism. It also acts as a buffer in acid-base balance. In the gastrointestinal tract, hyperosmotic sodium phosphate solution draws water into the lumen, inducing bowel evacuation.
| Metabolism | Sodium phosphates are not metabolized; they are absorbed in the small intestine and excreted renally. Phosphate homeostasis is regulated by the kidneys, parathyroid hormone, and vitamin D. |
| Excretion | Renal: >90% of absorbed phosphate is excreted renally, primarily as inorganic phosphate; fecal elimination accounts for <10%. |
| Half-life | Not applicable; phosphate is an endogenous ion with rapid equilibration. Serum phosphate half-life is approximately 30 minutes due to renal clearance and cellular uptake. |
| Protein binding | ~10-20% bound to albumin and other plasma proteins. |
| Volume of Distribution | Approximately 0.25-0.5 L/kg, reflecting distribution mainly in extracellular fluid and bone. |
| Bioavailability | Oral: 60-80% of ingested phosphate is absorbed (variable, depends on intestinal pH and vitamin D status). |
| Onset of Action | Oral: 2-4 hours for cathartic effect; IV: within minutes for serum phosphate elevation. |
| Duration of Action | Oral: cathartic effect lasts 3-6 hours; IV: serum phosphate elevation persists 4-6 hours depending on renal function. |
| Molecular Weight | 141.96 |
Oral: 3.75-7.5 g (15-30 mmol phosphate) 1-4 times daily. IV: 0.3-0.5 mmol/kg over 6-12 hours.
| Dosage form | SOLUTION |
| Renal impairment | GFR <30 mL/min: Avoid use due to risk of hyperphosphatemia. GFR 30-50: Reduce dose by 50%. |
| Liver impairment | No specific adjustment recommended for Child-Pugh A or B. Child-Pugh C: Caution, monitor electrolytes. |
| Pediatric use | Oral: 2-3 mmol/kg/day divided in 4-6 doses. IV: 0.5-1 mmol/kg/day, infusion rate ≤0.5 mmol/kg/h. |
| Geriatric use | Start at lower end of dosing range; monitor renal function and serum phosphate closely. |
| 1st trimester | Safety not established; may cause hyperphosphatemia, hypocalcemia, or electrolyte disturbances. Use only if clearly needed and with caution. |
| 2nd trimester | Similar to t1; monitor electrolytes closely. Avoid prolonged use or high doses. |
| 3rd trimester | Use with caution; risk of maternal electrolyte imbalance and potential fetal effects, including seizures or arrhythmias. Preferred for bowel preparation only if benefits outweigh risks. |
Clinical note
Comprehensive clinical and safety monograph for SODIUM PHOSPHATES (SODIUM PHOSPHATES).
| Placental transfer | Limited data; phosphate ions cross the placenta to some extent. Potential for fetal hyperphosphatemia or hypocalcemia with high maternal doses. |
| Breastfeeding | Small amounts may be excreted into breast milk but are unlikely to cause adverse effects in the infant due to rapid clearance. However, laxatives are not typically recommended during breastfeeding; alternative therapies should be considered. Monitor infant for diarrhea or electrolyte disturbances if maternal use is necessary. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | No evidence of teratogenicity in animal studies. Limited human data; risk cannot be excluded. Use only if clearly needed, especially during organogenesis. |
| Fetal Monitoring | Monitor serum phosphate, calcium, potassium, and renal function. In pregnancy, monitor for signs of fluid overload or electrolyte disturbances. |
| Fertility Effects | No known adverse effects on fertility. Systemic absorption is minimal after oral administration; parenteral use may affect electrolyte balance but no direct reproductive toxicity reported. |
■ FDA Black Box Warning
There is no FDA black box warning for sodium phosphates.
| Serious Effects |
Concurrent use of oral sodium phosphate bowel preparations with other laxatives or enemasPre-existing hyperphosphatemiaHypocalcemiaRenal impairment (e.g., serum creatinine >2 mg/dL or CrCl <30 mL/min)Gastrointestinal obstruction, perforation, or severe ileusPatients with ascitesKnown hypersensitivity to sodium phosphate
| Precautions | Risk of acute kidney injury, especially with oral bowel preparations in patients with risk factors (e.g., renal impairment, decreased intravascular volume, use of ACE inhibitors/ARBs, NSAIDs, diuretics), Electrolyte disturbances: hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia, Seizures secondary to hypocalcemia, Cardiac arrhythmias, Use with caution in patients with renal failure, heart failure, ascites, or those on sodium-restricted diets |
| Food/Dietary | Avoid solid foods for at least 2 hours before and after administration. Can be taken with water or clear liquids. Avoid dairy products, fruit juices, or alcohol. A low-residue diet is recommended 1-2 days before bowel preparation. |
| Clinical Pearls | Sodium phosphate is a saline laxative used for bowel cleansing. Use with caution in patients with renal impairment, heart failure, or on medications affecting renal function due to risk of acute phosphate nephropathy. Ensure adequate hydration. Monitor electrolytes, especially in elderly or dehydrated patients. Avoid in patients with bowel obstruction or ileus. |
| Patient Advice | Drink clear fluids as directed to prevent dehydration. · Do not use if you have kidney disease, heart failure, or intestinal blockage. · Report severe abdominal pain, vomiting, or irregular heartbeat immediately. · Follow the prescribed dosing schedule exactly; do not take more than directed. |
Loading safety data…